EyeBrain tech to be used in Parkinson's trial

EyeBrain's tracker device is being used in a clinical trial to evaluate the dyskinesia induced by treating idiopathic Parkinson's patients with levodopa.

The endpoint of the 30-person trial is to find biomarkers for the late-onset complications of using levodopa, which, over time, induces dyskinesia in Parkinson's patients. The condition is characterized by abnormal movements primarily affecting the face and extending as far as the arms and legs.

"Patients suffering from idiopathic Parkinson's disease will undergo an acute test as part of a pre-operational assessment for stimulating the deep recesses of the brain," explained Jean-François Tison in a statement. The motricity effects of the treatment will be evaluated by measuring the speed of eye movements with the help of the EyeBrain tracker.

The EyeBrain tracker, which is used in the early diagnosis of Parkinsonian syndromes, is useful for a number of potential applications, including multiple sclerosis, according to the company release.

The company, which is based in Ivry-sur-Seine, France, employs 15 people. It has raised €1.2 million ($1.6 million) from the CapDecisif and G1J venture capital funds and already generates revenues through the sale of the EyeBrain tracker.

- see the EyeBrain release

Suggested Articles

About 10 months after first announcing the move, Google has finally subsumed the healthcare-focused efforts of DeepMind.

Amgen has tapped Adaptive Biotechnologies to deliver next-generation sequencing assays as it moves its blood cancer drugs toward approval.

Bayer led One Drop’s $40 million series B round and licensed its technology for its “bio-digital efforts” in areas such as cancer and heart disease.